The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Antifibrogenic role of the cannabinoid receptor CB2 in the liver
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfaffl, M. W. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.e36 · Cited by 7,376
Woessner, J. F. (1961) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(61)90291-0 · Cited by 3,840
Extension of Life-Span with Superoxide Dismutase/Catalase Mimetics
Melov, S., Ravenscroft, J., Malik, S., Gill, M. S., Walker, D. W., Clayton, P. E., Wallace, D. C., Malfroy, B., Doctrow, S. R., & Lithgow, G. J. (2000) · Science · doi:10.1126/science.289.5484.1567 · Cited by 912
Kato, J.-Y., Matsuoka, M., Polyak, K., Massague, J., & Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90257-7 · Cited by 720
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.-M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 709
Járai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14136 · Cited by 599
Self-citationImmunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T., Zimmer, A., Felder, C. C., Glass, M., & Zimmer, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00211-9 · Cited by 544
Self-citationRepression of gene expression by oxidative stress
Morel, Y., & Barouki, R. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3420481 · Cited by 542
Pharmacology of Cannabinoid Receptor Ligands
Pertwee, R. G. (1999) · Current Medicinal Chemistry · doi:10.2174/0929867306666220401124036 · Cited by 526
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors
Casanova, M., Blázquez, C., Martínez‐Palacio, J., Villanueva, C., Fernández‐Aceñero, M. J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16116 · Cited by 437
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Also, the expression of CB2 receptors was found to be strongly induced in liver biopsy specimens from patients with active cirrhosis of various etiologies, particularly in non-parenchymal cells located within and at the edge of fibrous septa (Julien et al., 2005).”
BackgroundInfluentialPathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
MUSSO, G., GAMBINO, R., & CASSADER, M. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 681
Endocannabinoid signaling at the periphery: 50 years after THC
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.008 · Cited by 646
Self-citationCB2: a cannabinoid receptor with an identity crisis
Atwood, B. K., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00729.x · Cited by 619
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
Cannabinoids as Novel Anti-Inflammatory Drugs
Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.93 · Cited by 555
“CB2 receptors are also expressed in myofibroblasts, inflammatory cells and biliary epithelial cells [69].”
Peripheral cannabinoid receptor, CB2, regulates bone mass
Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., Tam, J., Attar-Namdar, M., Kram, V., Shohami, E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504187103 · Cited by 536
Self-citationCB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Teixeira-Clerc, F., Julien, B., Grenard, P., Van Nhieu, J. T., Deveaux, V., Li, L., Serriere-Lanneau, V., Ledent, C., Mallat, A., & Lotersztajn, S. (2006) · Nature Medicine · doi:10.1038/nm1421 · Cited by 528
Self-citationLigresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
Pacher, P., & Mechoulam, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.01.001 · Cited by 414
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
CB 1 and CB 2 Receptor Pharmacology
Howlett, A. C., & Abood, M. E. (2017) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.03.007 · Cited by 375
Bioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
SUGIURA, T., KISHIMOTO, S., OKA, S., & GOKOH, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 352
Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity
Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., de Petrocellis, L., Ullmer, C., Rothenhäusler, B., Perret, C., van Gils, N., et al. (2017) · Nature Communications · doi:10.1038/ncomms13958 · Cited by 349
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Daily Cannabis Smoking as a Risk Factor for Progression of Fibrosis in Chronic Hepatitis C *
Hézode, C., Roudot-Thoraval, F., Nguyen, S., Grenard, P., Julien, B., Zafrani, E.-S., Pawlostky, J.-M., Dhumeaux, D., Lotersztajn, S., & Mallat, A. (2005) · Hepatology · doi:10.1002/hep.20733 · Cited by 293
Self-citationEndocannabinoids and the regulation of their levels in health and disease
Di Marzo, V., & Petrosino, S. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32803dbdec · Cited by 289
Non-alcoholic fatty liver disease pathogenesis: The present and the future
Petta, S., Muratore, C., & Craxì, A. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.01.004 · Cited by 285
Hepatic stellate cells and the reversal of fibrosis
Kisseleva, T., & Brenner, D. A. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04584.x · Cited by 278
Hepatic microcirculation and mechanisms of portal hypertension
Gracia-Sancho, J., Marrone, G., & Fernández-Iglesias, A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0097-3 · Cited by 274
Wright, K. L., Duncan, M., & Sharkey, K. A. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707486 · Cited by 264
Wallace, K., Burt, A. D., & Wright, M. C. (2008) · Biochemical Journal · doi:10.1042/bj20071570 · Cited by 262
Louvet, A., Teixeira-Clerc, F., Chobert, M.-N., Deveaux, V., Pavoine, C., Zimmer, A., Pecker, F., Mallat, A., & Lotersztajn, S. (2011) · Hepatology · doi:10.1002/hep.24524 · Cited by 261
Self-citationEndocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
Pacher, P., & Haskó, G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707582 · Cited by 217
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis
Mallat, A., & Lotersztajn, S. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00230.2013 · Cited by 211
“In contrast to CB1dependent effects, an increase in CB2 signaling is associated with hepatoprotective effects, reduced liver inflammation, and improved liver fibrogenesis (21, 37, 52, 86).”
BackgroundSelf-citationPathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Self-citationInhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver
Habib, A., Chokr, D., Wan, J., Hegde, P., Mabire, M., Siebert, M., Ribeiro-Parenti, L., Le Gall, M., Lettéron, P., Pilard, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316137 · Cited by 91
Self-citationNicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) and liver fibrosis: A review
Mortezaee, K. (2018) · Cell Biochemistry and Function · doi:10.1002/cbf.3351 · Cited by 72
Involvement of the endocannabinoid system in periodontal healing
Kozono, S., Matsuyama, T., Biwasa, K. K., Kawahara, K.-I., Nakajima, Y., Yoshimoto, T., Yonamine, Y., Kadomatsu, H., Tancharoen, S., Hashiguchi, T., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.080 · Cited by 62
“Expression of CB1/CB2 receptors at wound sites in the present study is in accordance with a study stating that expression of CB1 and CB2 receptors is upregulated at wound sites in the liver [22,23].”
ResultCannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts
Garcia-Gonzalez, E., Selvi, E., Balistreri, E., Lorenzini, S., Maggio, R., Natale, M.-R., Capecchi, P.-L., Lazzerini, P.-E., Bardelli, M., Laghi-Pasini, F., et al. (2009) · Rheumatology · doi:10.1093/rheumatology/kep189 · Cited by 63
New trends for the medical treatment of endometriosis
Rocha, A. L. L., Reis, F. M., & Petraglia, F. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.683783 · Cited by 60
Chobert, M.-N., Couchie, D., Fourcot, A., Zafrani, E.-S., Laperche, Y., Mavier, P., & Brouillet, A. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2011.143 · Cited by 44
Fu, Q., Zheng, Y., Dong, X., Wang, L., & Jiang, C. G. (2017) · Oncotarget · doi:10.18632/oncotarget.21975 · Cited by 40
“CB2R agonists induced both growth arrest and apoptosis in myofibroblasts derived from cirrhotic liver [18].”
Background
Metadata
- Authors
- Julien, B., Grenard, P., Teixeira-Clerc, F., Van Nhieu, J. T., Li, L., Karsak, M., Zimmer, A., Mallat, A., & Lotersztajn, S.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 128
- Issue
- 3
- Pages
- 742-755
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2163346237
- Cited by
- 470
- References
- 52
- FWCI
- 19.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.